
|Articles|September 12, 2022
Why eConsent Primes Studies & Patients for Success
Author(s)Medable
According to a survey conducted by Florence Healthcare, 47% of research sites had adopted eConsent by December 2020, just 8 months after the WHO declared an official pandemic. By July 2021, 75% of research sites had either used it or were looking into it. In conclusion - a decentralized consent process is here to stay. Learn why Medable's Total eConsent offering is the industry-leading remote consent technology, and how it can reduce your enrolment timelines by 50%.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook
2
Novartis’ Q4 Recap Shows Signs of Looming Patent Cliff
3
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
4
FDA Rejects AstraZeneca’s Application for Subcutaneous Indication of Saphnelo
5